Ranked #1 in 8 out of the 10 evaluated specialties by U.S. News
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
The Thalassemia Program at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center treats all forms of the disease, including thalassemia minor or trait, thalassemia intermedia and thalassemia major (Cooley’s anemia), as well as rare forms of the disease such as hemoglobin E-beta thalassemia and hemoglobin H-alpha thalassemia. Because of our innovative approach, we are one of only six programs designated as centers of excellence in thalassemia by the National Cooley’s Anemia Foundation and one of only seven centers sponsored by the federal Centers for Disease Control and Prevention for the prevention of thalassemia complications.
Dana-Farber/Boston Children’s is an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children’s Hospital. We offer, in one specialized program, the full spectrum of services that are needed for diagnosis, treatment and ongoing care of even the rarest and hard-to-treat conditions.
The Thalassemia Program is staffed by a diverse team of thalassemia specialists, including experts in hematology, transfusion medicine and genetics. Because of the complexity of the disease, other medical specialists, including cardiologists, endocrinologists and gastroenterologists, are also part of the team. A full-time nurse practitioner coordinates care for our patients and their families.
Scientists and clinicians in our Thalassemia Program are developing new methods for the diagnosis and treatment of the disease, including new drugs and treatment options, as well as studying the genes that prevent hemoglobin production, a hallmark of thalassemia.
Learn more about our Thalassemia Program on the Dana-Farber/Boston Children’s website.
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”